International

Featured publication

Renal anaemia: recent developments, innovative approaches and future directions for improved management. 

• Published on 11 December 2006
• Nephrology (Carlton). 2006 Dec;11(6):542-8.

Department of Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia. peter.kerr@med.monash.edu.au

The morbidity, mortality and economic burden of chronic kidney disease (CKD) and associated anaemia are substantial. With the increasing numbers of patients who are likely to be affected in the future, approaches are required to improve anaemia management without increasing the burden on health-care professionals. A multidisciplinary approach to treatment, where early initiation of erythropoiesis-stimulating agents (ESA) is encouraged, may improve patient outcomes. Recent studies also suggest that the early use of iron therapy in patients with CKD not on dialysis may be associated with beneficial effects on haemoglobin levels. Another strategy to reduce the burden on health-care providers is to simplify anaemia management by extending the administration interval of ESA. Indeed, recent studies have explored the efficacy of extending the administration interval of ESA in clinical practice in CKD patients on dialysis and not on dialysis. The ability to maintain haemoglobin levels within guideline ranges at extended administration intervals may improve patient care and reduce the workload of health-care providers.

Read the full text article*
(Right click on link – select Save Target As. Save file to your desktop)

  * Adobe Acrobat Reader and the FileOpen client plugin for Acrobat Reader is required to view and print this document. Please use the following button to download FileOpen if you don't already have it.
Note: an Internet connection is required in order to open / view this downloaded secure publication.